Skip to main content

ADVM

Stock
Health Care
Biotechnology

Performance overview

ADVM Price
Price Chart

Forward-looking statistics

Beta
Risk

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

Company info

SectorHealth Care
IndustryBiotechnology
Employees147
Market cap$152.6M

Fundamentals

Enterprise value$55.0M
Revenue$1.0M
Revenue per employee
Profit margin0.00%
Debt to equity352.65

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$7.22
Dividend per share
Revenue per share$0.05
Avg trading volume (30 day)$772K
Avg trading volume (10 day)$1M
Put-call ratio

Macro factor sensitivity

Growth+25.3
Credit-17.3
Liquidity-11.2
Inflation+24.8
Commodities+11.4
Interest Rates+1.2

Valuation

Dividend yield0.00%
PEG Ratio-0.43
Price to sales47.63
P/E Ratio-0.43
Enterprise Value to Revenue55.01
Price to book1.80

Upcoming events

Next earnings dayAugust 12, 2025
Next dividend day
Ex. dividend day

News

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

Adverum Biotechnologies (ADVM) came out with a quarterly loss of $1.30 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $3.30 per share a year ago.

Zacks Investment Research (November 5, 2024)
Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022

Adverum Biotechnologies Inc (NASDAQ: ADVM) announced a restructuring plan, including reductions in headcount and expenses, to prioritize its clinical development of ADVM-022, a single intravitreal injection for wet age-related macular degeneration (AMD). Adverum intends these.

Benzinga (July 7, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free